Method of reducing adenoviral vector-associated tts
AssigneesVector Sciences, Inc., Beth Israel Deaconess Medical Center, Inc.
InventorsPeter Abbink, Dan H. Barouch
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of reducing the risk of thrombosis with thrombocytopenia syndrome (TTS) associated with adenoviral vector therapy.
Claims25
A method of treating a subject at risk of thrombosis with thrombocytopenia syndrome (“TTS”) associated with adenoviral vector therapy, comprising administering to a subject at risk of TTS low negative charge adenoviral vector therapy.
A method of reducing the risk of thrombosis with thrombocytopenia syndrome (“TTS”) associated with adenoviral vector therapy, comprising administering to a subject at risk of TTS low negative charge adenoviral vector therapy.
6-13. (canceled)
24-26. (canceled)
28-29. (canceled)
32-36. (canceled)
39-71. (canceled)
Dependencies are inferred from the claim text.